Evidence map›Paper›PMID 35524940›Full record

ArticleCancer science2022

Machine learning diagnosis by immunoglobulin N-glycan signatures for precision diagnosis of urological diseases.

Hiromichi Iwamura, Kei Mizuno, Shusuke Akamatsu, Shingo Hatakeyama, Yuki Tobisawa, Shintaro Narita, Takuma Narita, Shinichi Yamashita, Sadafumi Kawamura, Toshihiko Sakurai and 11 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 1 country.

Hiromichi IwamuraDepartment of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Kei MizunoDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Shusuke AkamatsuDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Shingo HatakeyamaDepartment of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.ORCID https://orcid.org/0000-0002-0026-4079
Yuki TobisawaDepartment of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Shintaro NaritaDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.ORCID https://orcid.org/0000-0003-2988-1860
Takuma NaritaDepartment of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Shinichi YamashitaDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Sadafumi KawamuraDepartment of Urology, Miyagi Cancer Center, Natori, Japan.
Toshihiko SakuraiDepartment of Urology, Yamagata University Graduate School of Medicine, Yamagata, Japan.
Naoki FujitaDepartment of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Hirotake KodamaDepartment of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.ORCID https://orcid.org/0000-0002-5071-5149
Daisuke NoroDepartment of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Ikuko KakizakiDepartment of Glycotechnology, Center for Advanced Medical Research, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Shigeyuki NakajiDepartment of Social Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Ken ItohDepartment of Glycotechnology, Center for Advanced Medical Research, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Norihiko TsuchiyaDepartment of Urology, Yamagata University Graduate School of Medicine, Yamagata, Japan.
Akihiro ItoDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tomonori HabuchiDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Chikara OhyamaDepartment of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Tohru YoneyamaDepartment of Glycotechnology, Center for Advanced Medical Research, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.ORCID https://orcid.org/0000-0002-1098-407X
Hirosaki University · JPAkita University · JPKyoto University · JPTohoku University · JPYamagata University · JPMiyagi Prefectural Hospital Organization · JP

Funding

Center of Innovation Program JPMJCE1302Center of Innovation Program R03W14Japan Society for the Promotion of Science 20K18083Japan Society for the Promotion of Science 20K18130
6 · The paper itself

Abstract

Early diagnosis of urological diseases is often difficult due to the lack of specific biomarkers. More powerful and less invasive biomarkers that can be used simultaneously to identify urological diseases could improve patient outcomes. The aim of this study was to evaluate a urological disease-specific scoring system established with a machine learning (ML) approach using Ig N-glycan signatures. Immunoglobulin N-glycan signatures were analyzed by capillary electrophoresis from 1312 serum subjects with hormone-sensitive prostate cancer (n = 234), castration-resistant prostate cancer (n = 94), renal cell carcinoma (n = 100), upper urinary tract urothelial cancer (n = 105), bladder cancer (n = 176), germ cell tumors (n = 73), benign prostatic hyperplasia (n = 95), urosepsis (n = 145), and urinary tract infection (n = 21) as well as healthy volunteers (n = 269). Immunoglobulin N-glycan signature data were used in a supervised-ML model to establish a scoring system that gave the probability of the presence of a urological disease. Diagnostic performance was evaluated using the area under the receiver operating characteristic curve (AUC). The supervised-ML urologic disease-specific scores clearly discriminated the urological diseases (AUC 0.78-1.00) and found a distinct N-glycan pattern that contributed to detect each disease. Limitations included the retrospective and limited pathological information regarding urological diseases. The supervised-ML urological disease-specific scoring system based on Ig N-glycan signatures showed excellent diagnostic ability for nine urological diseases using a one-time serum collection and could be a promising approach for the diagnosis of urological diseases.

Indexed as

Kidney NeoplasmsProstatic NeoplasmsUrinary Bladder NeoplasmsBiomarkers, TumorHumansImmunoglobulinsMachine LearningMalePolysaccharidesRetrospective StudiesBiomarkers, TumorImmunoglobulinsPolysaccharidesbiomarkerglycosylationimmunoglobulinmachine learningurologic disease

Identifiers

PMID35524940
PMCPMC9277255
OpenAlexW4229012106

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.